SCHEMBL7220189

SCHEMBL7220189

[CH2]c1ccc(C(=O)OC(C)(C)C)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SLC7A5 Q01650 1/20 0.33
ELANE P08246 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.32
SIRT1 Q96EB6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22835128 0.86 HDAC4 (0.44) HTTTSHRHDAC4HDAC6KMT2A
SCHEMBL22835130 0.79 HDAC4 (0.44) HTTTSHRHDAC4HDAC6KMT2A
SCHEMBL2939599 0.79 POLB (0.46) HTTTSHRHDAC4HDAC6ALDH1A1
SCHEMBL1505245 0.79 HTT (0.58) HTTTSHRKMT2AMEN1CYP1A2
SCHEMBL1179297 0.78 KMT2A (0.54) HTTTSHRKMT2AMEN1CYP1A2
SCHEMBL8502338 0.76 HTT (0.36) HTTTSHRHDAC4HDAC6KMT2A
SCHEMBL1185540 0.75 ALDH1A1 (0.40) HTTTSHRHDAC4HDAC6CA12
SCHEMBL1522372 0.74 HDAC4 (0.58) TSHRHDAC4HDAC6KMT2AMEN1
SCHEMBL20233526 0.74 HDAC4 (0.46) HTTTSHRHDAC4HDAC6ALDH1A1
SCHEMBL13141409 0.74 HTT (0.49) HTTTSHRKMT2ACYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6503898-B1 Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed